Allogene Therapeutics reported interim results from a pivotal Phase 2 Alpha3 trial in first-line consolidation large B-cell lymphoma, suggesting its allogeneic CAR T cemacabtagene ansegedleucel (cema-cel) can deepen minimal residual disease (MRD) negativity compared with observation. Allogene said 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation group at the day-45 assessment cutoff. The company characterized the interim futility analysis as clearing a benchmark threshold in published literature that may translate into delayed relapse, while also reporting a safety profile without the severe immune or neurologic toxicity typically associated with personalized CAR T experiences. Allogene is continuing enrollment and expects additional data from the ongoing study in 2027. The update further validates the strategy to position donor-derived CAR T earlier in disease courses, where a higher chance of preventing recurrence could improve outcomes and reduce reliance on individualized manufacturing.